INmune Bio (NASDAQ:INMB) received a $13.00 target price from research analysts at Maxim Group in a report issued on Thursday, TipRanks reports. The firm presently has a “buy” rating on the stock. Maxim Group’s target price would indicate a potential upside of 20.93% from the stock’s previous close.
NASDAQ INMB remained flat at $$10.75 on Thursday. 5,730 shares of the company’s stock traded hands, compared to its average volume of 16,584. INmune Bio has a 12-month low of $7.00 and a 12-month high of $11.50.
In other news, CFO David J. Moss acquired 5,000 shares of the stock in a transaction on Monday, May 6th. The shares were purchased at an average cost of $9.00 per share, for a total transaction of $45,000.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Linda F. Powers acquired 61,667 shares of the stock in a transaction on Wednesday, May 8th. The shares were purchased at an average price of $9.00 per share, for a total transaction of $555,003.00. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 77,767 shares of company stock worth $709,893.
About INmune Bio
INmune Bio Inc, a clinical-stage immunotherapy company, focuses on engineering and harnessing the innate immune system to treat the patient's cancer. The company intends to develop and commercialize product candidates to treat diseases comprising hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma; and INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation, including elevated levels of myeloid derived suppressor cells in their blood.
Further Reading: What is a Derivative?
Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.